Ampersand-backed Roadrunner Pharmacy sold to Vets First Choice

Ampersand Capital Partners announced the sale of Roadrunner Pharmacy to Vets First Choice, a provider of tech-enabled healthcare services for pet and equine veterinary doctors. In 2012 Ampersand invested in a partial recapitalization of Roadrunner, which supplies prescription drugs to vet clinics and pet owners.

Update: HCAP Partners, a California-based mezzanine debt and private equity firm, also announced the sale of its stake in Roadrunner in a press release.


WELLESLEY, Mass.Aug. 10, 2017 /PRNewswire/ —  Ampersand Capital Partners announced today that portfolio company Roadrunner Pharmacy has been acquired by Vets First Choice.  In 2012, Ampersand invested in a partial recapitalization that was Roadrunner’s first and only institutional equity financing, consistent with Ampersand’s strategy of partnering with founder owned and operated companies.  Over the last five years, Roadrunner experienced significant growth in revenues and EBITDA, leading to this successful exit.

Based in Phoenix, Arizona, Roadrunner is a leading provider of customized prescription medication to veterinary clinics and pet owners across the US.  Licensed in all 50 states, Roadrunner employs more than 250 pharmacists, pharmacy technicians, sales and service professionals.  The pharmacy has built its reputation on delivering high quality compounded medications in a wide range of proprietary dose forms and exceptional customer service, including free next-day shipping.

“We’re enthusiastic to enable access to specialty pharmacy services via our prescription management platform for veterinarians and patients,” said Benjamin Shaw, Founder and CEO of Vets First Choice.  “The combination of these capabilities helps practices streamline workflow, improve service, and enhance client communication.”

About Vets First Choice

Vets First Choice is a leading provider of technology-enabled healthcare services for companion and equine veterinary practitioners. Founded in 2010, the company partners with veterinarians to create insight into gaps in patient care and offers professionalized pro-active prescription management to drive client engagement and improve compliance. Its services result in better prescription compliance, increased client engagement, and improved practice revenues and profitability. For more information, please visit

About Ampersand Capital Partners

Ampersand is a middle market private equity firm with a focus on growth equity investments in the healthcare sector.  Over the past two decades, Ampersand has managed more than $1 billion in private equity partnerships.  Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams.  Additional information about Ampersand is available at

Do you want exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more? Get your FREE trial to Buyouts! Or subscribe now!